2025
Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies
Chen F, Esmaili R, Khajir G, Zeevi T, Gross M, Leapman M, Sprenkle P, Justice A, Arora S, Weinreb J, Spektor M, Huber S, Humphrey P, Levi A, Staib L, Venkataraman R, Martin D, Onofrey J. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. European Urology Oncology 2025 PMID: 39924390, DOI: 10.1016/j.euo.2025.01.005.Peer-Reviewed Original ResearchProstate cancerPrediction of clinically significant prostate cancerClinical dataProstate-specific antigen levelClinically significant prostate cancerProstate magnetic resonance imagingSeverity of prostate cancerCombination of clinical featuresPrediction of csPCaSignificant prostate cancerProstate Imaging-ReportingCore needle biopsyRetrospective analysis of dataDecision curve analysisReducing unnecessary biopsiesProstate cancer diagnosisReceiver operating characteristic curveArea under the receiver operating characteristic curveFalse-negative rateMagnetic resonance imagingPersonalized risk assessmentAntigen levelsNeedle biopsyPatient ageUnnecessary biopsies
2023
Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUC
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease oneMP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY
Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.Peer-Reviewed Original ResearchDistribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2019
PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2
Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.Peer-Reviewed Original Research
2017
The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.
Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.Peer-Reviewed Original ResearchPI-RADS 4 lesionsPositive predictive valueBiopsy-naïve menNaïve menPredictive valuePI-RADS 3PI-RADS version 2PI-RADS 4Cancer detection rateChi-square testPSA densityEntire cohortMean ageFusion biopsyProstate cancerSingle lesionLesion locationGroup 2Group 1Group 3LesionsAssessment scoresLesion numberCategorical variablesFurther assessment
2016
PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS?
Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Journal Of Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.Peer-Reviewed Original ResearchMP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER
Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER. Journal Of Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.Peer-Reviewed Original ResearchMRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancerMRI-US fusion targeted biopsy results in men with a history of prior cancer.
Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.Peer-Reviewed Original ResearchMRI-US fusionGleason scoreActive surveillanceFusion biopsySignificant cancerProstate cancerGleason 6 prostate cancerPre-biopsy mpMRIPrevious prostate biopsyAppropriate risk stratificationMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreUpstaging rateC cancerPrior cancerPrior biopsyMapping biopsyRisk stratificationHigher PSABiopsy resultsProstate biopsyInclusion criteriaMp-MRIPatient basisMRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsyProstate cancer detection rates of negative MP-MRIs.
Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.Peer-Reviewed Original ResearchTemplate mapping biopsyNegative predictive valueNegative MRIMapping biopsyActive surveillanceSignificant cancerProstate cancer detection rateSignificant CaPMRI-US fusion biopsyHigh negative predictive valueBiopsy-naive menPrior negative biopsyBiopsy-naïve patientsCancer detection rateProstate cancer detectionDiffusion-weighted imagingDynamic contrast enhancementNIH National InstituteNaïve patientsNegative menGleason 7High suspicionNegative biopsyPatient counselingGleason 4
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply